Adoptive Therapy with T Cells/NK Cells

[1]  W. Murphy,et al.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[3]  B. Fox,et al.  Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. , 2005, Cancer research.

[4]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[5]  B. Barlogie,et al.  Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma , 2005, Bone Marrow Transplantation.

[6]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[7]  J. Shaw,et al.  Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire , 2005, Bone Marrow Transplantation.

[8]  Stephen P. Schoenberger,et al.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death , 2005, Nature.

[9]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[10]  M. Bevan,et al.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.

[11]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[12]  E John Wherry,et al.  The role of programming in memory T-cell development. , 2004, Current opinion in immunology.

[13]  R. Weissleder,et al.  In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. , 2003, Cancer research.

[14]  S. Grupp,et al.  Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. , 2003, Blood.

[15]  D. Vesole,et al.  IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial , 2003, Bone Marrow Transplantation.

[16]  M. Farrar,et al.  In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells , 2003, The Journal of experimental medicine.

[17]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[18]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[19]  Sven Becker,et al.  Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. , 2002, Blood.

[20]  A. Theofilopoulos,et al.  T cell homeostatic proliferation elicits effective antitumor autoimmunity. , 2002, The Journal of clinical investigation.

[21]  E. Wherry,et al.  Vaccines: Effector and memory T-cell differentiation: implications for vaccine development , 2002, Nature Reviews Immunology.

[22]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[23]  J. Miller,et al.  Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. , 2001, Blood.

[24]  W. Murphy,et al.  Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. , 2001, Blood.

[25]  M. Caligiuri,et al.  Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells , 2001, The Journal of experimental medicine.

[26]  C. Bradford,et al.  Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  D. Longo,et al.  Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V. Sondak,et al.  Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[30]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[31]  S. Weiss,et al.  Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Jeffrey S. Miller,et al.  Role of monocytes in the expansion of human activated natural killer cells. , 1992, Blood.

[33]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[34]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[35]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[36]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[37]  Susan M. Kaech,et al.  Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .

[38]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.

[39]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[40]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.